ACCESS Newswire·Nov 11, 2026, 8:10 AM ET

Valion Bio Reinforces Commitment to American Troops; Discusses Entolimod with Attendees at RW Baird's National Security Conference

Valion Bio, Inc. announced it will attend RW Baird's 2026 National Security Conference on November 17 in Washington, D.C.
Management will discuss Entolimod's potential to protect U.S. service members from radiation exposure with defense stakeholders & institutional investors.
The National Institute of Allergy & Infectious Diseases (NIAID) is funding a therapeutic study to evaluate a single dose of Entolimod given 24 hours post-radiation for survival improvement in an animal model of gastrointestinal acute radiation syndrome.
Top-line results from the NIAID-funded efficacy study are expected in early December.
Entolimod is being developed as a countermeasure for both bone marrow & gastrointestinal forms of acute radiation syndrome.
Valion briefed Pentagon officials in April & held a joint briefing with senior U.S. defense officials & BARDA in May.
The U.S. House Armed Services Committee called for a plan to develop resources & a fielding plan for radiation/nuclear countermeasures in June.
Entolimod is a TLR5 agonist that has received Fast Track & Orphan Drug designations from the FDA.
The Company holds an exclusive, worldwide license from Statera Biopharma to develop & commercialize Entolimod.
Valion is also advancing Entolasta, a next-generation TLR5 agonist for potential use in oncology supportive care.
Valion's subsidiary, Velocity Bioworks, operates as a biologics contract development & manufacturing organization.